表紙
市場調査レポート

C型肝炎:世界の治験レビュー

Hepatitis C Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 222299
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
C型肝炎:世界の治験レビュー Hepatitis C Global Clinical Trials Review, H2, 2014
出版日: 2014年11月28日 ページ情報: 英文 214 Pages
概要

C型肝炎とは、肝臓がC型肝炎ウィルスによって炎症を起こした状態を指します。C型肝炎ウィルスは感染した血液と接触することによって広がります。また、出産時に母親から赤ん坊にうつったり、感染者との性交によっても感染します。

当レポートでは、C型肝炎に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

イントロダクション

  • C型肝炎
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数: C型肝炎治験件数の感染症治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数: C型肝炎治験件数の感染症治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

未完了の治験 C型肝炎

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - C型肝炎治療薬

有望な薬剤

  • 最新治験ニュース: C型肝炎

治験のプロファイル

  • 代表的な企業の治験の概要
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Vertex Pharmaceuticals Incorporated
    • Johnson & Johnson
    • C. H. Boehringer Sohn AG & Co. KG
    • AbbVie Inc.
    • Novartis AG
    • GlaxoSmithKline plc
  • 代表的な研究機関/病院の治験の概要
    • The National Institute of Allergy and Infectious Diseases
    • French National Agency for Research on AIDS and Viral Hepatitis
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • National Taiwan University Hospital
    • U.S. Department of Veterans Affairs
    • Kaohsiung Medical University Chung-Ho Memorial Hospital
    • 九州大学
    • University Health Network
    • Medical University of Vienna
    • 大阪大学

5大治験プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC2438CTIDB

GlobalData's clinical trial report, "Hepatitis C Global Clinical Trials Review, H2, 2014" provides data on the Hepatitis C clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis C. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis C. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Hepatitis C
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Hepatitis C
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Hepatitis C Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Hepatitis C
    • Nov 11, 2014: Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
    • Nov 11, 2014: Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
    • Nov 11, 2014: Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naive and Difficult-to-Cure Patients
    • Nov 11, 2014: Enanta Announces Results From Phase 2b PEARL-I Study In Genotype 4 Chronic Hepatitis C Patients At The Liver Meeting 2014
    • Nov 11, 2014: AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting 2014
    • Nov 11, 2014: AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting 2014
    • Nov 10, 2014: Very good results of Civacir (Hepatitis C Immune Globulin) US Phase III clinical trial
    • Nov 08, 2014: ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
    • Nov 08, 2014: Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis
    • Nov 08, 2014: Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
    • Nov 08, 2014: Achillion Reports Data in Three Preclinical Posters on ACH-3422 at the Liver Meeting 2014 (AASLD)
    • Nov 06, 2014: Alios BioPharma to Present Preclinical Data on its Anti-HCV Nucleotides AL-335
    • Nov 06, 2014: Alios BioPharma to Present Preclinical Data on its Anti-HCV Nucleotides AL-516
    • Nov 05, 2014: New vaccine generates strong immune response against hepatitis C
    • Nov 03, 2014: Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
    • Oct 22, 2014: A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History
    • Oct 10, 2014: BIT225 Trial Results Show Effective Cure Of Hepatitis C
    • Oct 10, 2014: Phase II IMPACT study initiated to evaluate Simeprevir in combination with Sofosbuvir and Daclatasvir to treat genotype 1 and 4 hepatitis C patients
    • Oct 08, 2014: Achillion To Present Updated Clinical HCV Data On ACH-3102 At The American Association For The Study Of Liver Diseases (AASLD) Annual Meeting
    • Oct 08, 2014: TT-­034 HCV Trial Update
    • Oct 07, 2014: Immunotech Laboratories Updates Progress on Negotiations for Phase III Testing on its Treatments for HIV/AIDS and Hepatitis C Viruses in Macedonia and Serbia
    • Sep 24, 2014: Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection
    • Sep 15, 2014: Alios BioPharma Presents Data on its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C
    • Sep 10, 2014: Enanta Pharmaceuticals Announces the Initiation of Phase 2b Clinical Trial with Regimen Containing HCV Protease Inhibitor ABT-493
    • Aug 28, 2014: Immunotech Laboratories Announces Successful Completion of Phase I and Phase II Field Trials of the Company's Patented Treatment of the HIV/AIDS and Hepatitis C Viruses
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Gilead Sciences, Inc.
      • Clinical Trial Overview of Gilead Sciences, Inc.
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • Vertex Pharmaceuticals Incorporated
      • Clinical Trial Overview of Vertex Pharmaceuticals Incorporated
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • C. H. Boehringer Sohn AG & Co. KG
      • Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
    • Clinical Trial Overview of Top Institutes / Government
      • The National Institute of Allergy and Infectious Diseases
      • Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases
      • French National Agency for Research on AIDS and Viral Hepatitis
      • Clinical Trial Overview of French National Agency for Research on AIDS and Viral Hepatitis
      • The National Institute of Diabetes and Digestive and Kidney Diseases
      • Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases
      • National Taiwan University Hospital
      • Clinical Trial Overview of National Taiwan University Hospital
      • U.S. Department of Veterans Affairs
      • Clinical Trial Overview of U.S. Department of Veterans Affairs
      • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Clinical Trial Overview of Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kyushu University
      • Clinical Trial Overview of Kyushu University
      • University Health Network
      • Clinical Trial Overview of University Health Network
      • Medical University of Vienna
      • Clinical Trial Overview of Medical University of Vienna
      • Osaka University
      • Clinical Trial Overview of Osaka University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Hepatitis C Therapeutics, Global, Clinical Trials by Region, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2014*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2014*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hepatitis C Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Hepatitis C Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Hepatitis C Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Vertex Pharmaceuticals Incorporated, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by French National Agency for Research on AIDS and Viral Hepatitis, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaohsiung Medical University Chung-Ho Memorial Hospital, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyushu University, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014*
  • Hepatitis C Therapeutics Clinical Trials Market, Global, Clinical Trials by Osaka University, 2014*

List of Figures

  • Hepatitis C Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2014*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2014*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top